5T1S

Irak4 kinase - compound 1 co-structure


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.207 
  • R-Value Observed: 0.207 

wwPDB Validation 3D Report Full Report


This is version 1.2 of the entry. See complete history


Literature

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.

Smith, G.F.Altman, M.D.Andresen, B.Baker, J.Brubaker, J.D.Chen, H.Chen, Y.Childers, M.Donofrio, A.Ferguson, H.Fischer, C.Fischmann, T.O.Gibeau, C.Hicks, A.Jin, S.Kattar, S.Kleinschek, M.A.Leccese, E.Lesburg, C.Li, C.Lim, J.Liu, D.Maclean, J.K.F.Mansoor, F.Moy, L.Y.Mulrooney, E.F.Necheva, A.S.Presland, J.Rakhilina, L.Yang, R.Torres, L.Zhang-Hoover, J.Northrup, A.

(2017) Bioorg Med Chem Lett 27: 2721-2726

  • DOI: 10.1016/j.bmcl.2017.04.050
  • Primary Citation of Related Structures:  
    5T1S, 5T1T

  • PubMed Abstract: 
  • Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. ...

    Interleukin-1 receptor associated kinase 4 (IRAK4) has been implicated in IL-1R and TLR based signaling. Therefore selective inhibition of the kinase activity of this protein represents an attractive target for the treatment of inflammatory diseases. Medicinal chemistry optimization of high throughput screening (HTS) hits with the help of structure based drug design led to the identification of orally-bioavailable quinazoline based IRAK4 inhibitors with excellent pharmacokinetic profile and kinase selectivity. These highly selective IRAK4 compounds show activity in vivo via oral dosing in a TLR7 driven model of inflammation.


    Organizational Affiliation

    Merck & Co., Inc., 33 Avenue Louis Pasteur, Boston, MA 02115, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Interleukin-1 receptor-associated kinase 4ABCD301Homo sapiensMutation(s): 0 
Gene Names: IRAK4
EC: 2.7.11.1
Find proteins for Q9NWZ3 (Homo sapiens)
Explore Q9NWZ3 
Go to UniProtKB:  Q9NWZ3
NIH Common Fund Data Resources
PHAROS  Q9NWZ3
Protein Feature View
Expand
 ( Mouse scroll to zoom / Hold left click to move )
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
76Q
Query on 76Q

Download CCD File 
A, B, C, D
5-[3-(3,5-dimethylphenyl)-4-[4-(methylamino)butyl]quinolin-6-yl]pyridin-3-ol
C27 H29 N3 O
XXIAQHKXGSSEJL-UHFFFAOYSA-N
 Ligand Interaction
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
SEP
Query on SEP
A,B,C,DL-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A,B,C,DL-PEPTIDE LINKINGC4 H10 N O6 PTHR
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
76QIC50:  84   nM  Binding MOAD
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 0.223 
  • R-Value Work: 0.207 
  • R-Value Observed: 0.207 
  • Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 144.34α = 90
b = 139.3β = 125.05
c = 88.09γ = 90
Software Package:
Software NamePurpose
AutoPROCdata scaling
XDSdata reduction
SCALAdata scaling
BUSTERrefinement

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

  • Deposited Date: 2016-08-22 
  • Released Date: 2017-05-03 
  • Deposition Author(s): Fischmann, T.O.

Revision History 

  • Version 1.0: 2017-05-03
    Type: Initial release
  • Version 1.1: 2017-06-28
    Changes: Database references
  • Version 1.2: 2017-11-22
    Changes: Refinement description